Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Microbiol Infect ; 16(2): 147-51, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19689464

ABSTRACT

The aim of this prospective cohort study was to determine the risk factors for community-acquired urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-positive Escherichia coli and the distribution of the ESBL enzyme types. Structured forms were filled in for patients diagnosed with community-acquired UTI in four different geographical locations in Turkey. The forms and the isolates were sent to the central laboratory at Baskent University Hospital, Ankara. Antimicrobial susceptibility was determined according to the CLSI criteria. PCR and DNA sequencing were used to characterize the bla(TEM), bla(CTX-M) and bla(SHV) genes. Multivariate analysis was performed using logistic regression. A total of 510 patients with UTI caused by Gram-negative bacteria were included in this study. ESBLs were detected in 17 of 269 (6.3%) uropathogenic E. coli isolates from uncomplicated UTIs and 34 of 195 (17.4%) E. coli isolates from complicated UTIs (p <0.001). According to multivariate analysis, more than three urinary tract infection episodes in the preceding year (OR 3.8, 95% CI 1.8-8.1, p <0.001), use of a beta-lactam antibiotic in the preceding 3 months (OR 4.6, 95% CI 2.0-0.7, p <0.001) and prostatic disease (OR 9.6, 95% CI 2.1-44.8, p 0.004) were found to be associated with ESBL positivity. The percentages of isolates with simultaneous resistance to trimethoprim-sulphamethoxazole, ciprofloxacin and gentamicin were found to be 4.6% in the ESBL-negative group and 39.2% in the ESBL-positive group (p <0.001). Forty-six of 51 ESBL-positive isolates (90.2%) were found to harbour CTX-M-15. Therapeutic alternatives for UTI, particularly in outpatients, are limited. Further clinical studies are needed to guide the clinicians in the management of community-acquired UTIs.


Subject(s)
Community-Acquired Infections/microbiology , Escherichia coli Infections/microbiology , Escherichia coli Proteins/biosynthesis , Urinary Tract Infections/microbiology , Uropathogenic Escherichia coli/enzymology , Uropathogenic Escherichia coli/isolation & purification , beta-Lactamases/biosynthesis , Adolescent , Adult , Aged , Animals , Anti-Bacterial Agents/pharmacology , Cohort Studies , DNA, Bacterial/genetics , Escherichia coli Proteins/classification , Escherichia coli Proteins/genetics , Female , Humans , Male , Microbial Sensitivity Tests/methods , Middle Aged , Polymerase Chain Reaction/methods , Pregnancy , Prospective Studies , Risk Factors , Sequence Analysis, DNA , Turkey , Uropathogenic Escherichia coli/drug effects , Young Adult , beta-Lactamases/classification , beta-Lactamases/genetics
2.
Ann Acad Med Singap ; 35(1): 11-6, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16470268

ABSTRACT

INTRODUCTION: The objective of this study was to compare the safety and efficacy of ceftazidime (2 g every 8 h), piperacillin/tazobactam (4 g/500 mg every 6 h), and meropenem (1 g every 8 h), when combined with amikacin (15 mg/kg once daily), in the empirical treatment of high-risk febrile neutropenic episodes in patients with haematological malignancy. MATERIALS AND METHODS: A prospective, comparative study designed in the haematology unit of a university hospital in Turkey. RESULTS: A total of 89 febrile episodes in 60 neutropenic patients were treated; 29 febrile episodes in 23 patients with ceftazidime plus amikacin (group 1), 30 episodes in 25 patients with piperacillin/tazobactam plus amikacin (group 2), and 30 episodes in 25 patients with meropenem plus amikacin (group 3). The 3 groups were comparable in terms of age, sex, underlying malignancy, pretherapy neutrophil counts, duration of neutropenia and types of infections. Neutropenia, since the start of fever, persisted for > or =10 days in all of the episodes in the 3 study groups. Nearly all of the episodes were seen in patients with acute leukaemia. In 25.8% (23/89) of the febrile neutropenia episodes, an aetiologic organism was isolated, with gram-negative bacteria being the most commonly isolated. The success without modification rates were 34.5%, 30% and 36.7% for groups 1, 2 and 3, respectively (P >0.05). After modification with a different class of antimicrobial therapy, the response rates increased to 65.5%, 63.3% and 70% for groups 1, 2 and 3, respectively (P >0.05). The mean duration of treatment and the time to defervescence were also comparable in all groups. In all arms, side effects were minimal. CONCLUSIONS: It is concluded that the 3 regimens were equally effective and safe in the empirical treatment of high-risk febrile neutropenic episodes.


Subject(s)
Amikacin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Ceftazidime/therapeutic use , Neutropenia/drug therapy , Penicillanic Acid/analogs & derivatives , Piperacillin/therapeutic use , Thienamycins/therapeutic use , Adolescent , Adult , Aged , Anti-Bacterial Agents/pharmacology , Ceftazidime/pharmacology , Drug Therapy, Combination , Female , Fever/etiology , Humans , Immunocompromised Host , Male , Meropenem , Middle Aged , Neutropenia/chemically induced , Neutropenia/physiopathology , Penicillanic Acid/pharmacology , Penicillanic Acid/therapeutic use , Piperacillin/pharmacology , Prospective Studies , Risk Assessment , Risk Factors , Tazobactam , Thienamycins/pharmacology
3.
Clin Lab Haematol ; 25(1): 63-5, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12542445

ABSTRACT

Thrombocytopenia is generally seen as a complication in typhoid fever. However, it can also be encountered as a presenting sign on admission. A 29-year-old man with complaints of fever and diarrhoea was hospitalized because of isolated thrombocytopenia encountered on routine complete blood count examination. The diagnosis of typhoid fever was established when Salmonella typhi was isolated from the blood cultures. The platelet count returned to normal level within the first week of ceftriaxone therapy. Possible mechanisms of thrombocytopenia were discussed.


Subject(s)
Thrombocytopenia/etiology , Typhoid Fever/complications , Typhoid Fever/diagnosis , Adult , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Humans , Male , Platelet Count , Salmonella typhi/isolation & purification , Thrombocytopenia/microbiology , Typhoid Fever/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...